Cogent Biosciences Inc reports results for the quarter ended in January - Earnings Summary

Cogent Biosciences

06/08/2024 15:20

* Cogent Biosciences Inc  COGT.OQ  reported a quarterly
adjusted
loss of 59 cents​​ per share for the quarter ended in January,
identical to the same quarter last year.  The mean expectation
of ten analysts for the quarter was for a loss of 56 cents per
share. Wall Street expected results to range from -66 cents
to -33 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Cogent Biosciences Inc's reported EPS for the quarter was
a loss
of 59 cents​.
    * The company reported a quarterly loss of $58.95 million.
    * Cogent Biosciences Inc shares had risen by 8.4% this
quarter and
gained 55.4% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had fallen by
about 6% in
the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 9 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for Cogent
Biosciences Inc is $17.00 
This summary was machine generated from LSEG data August 6 at
02:20 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2024      -0.56          -0.59          Missed
 Mar. 31 2024      -0.52          -0.62          Missed
 Dec. 31 2023      -0.56          -0.63          Missed
 Sep. 30 2023      -0.50          -0.64          Missed